St Jude Medical News

The Global Neuromodulation market is expected to grow at a CAGR of 16 percent over the period 2011-2015. One of the key factors contributing to this market growth is advancements in implantable neurostimulation devices.

"To get lifesaving drugs and devices to the patients that need them as quickly as possible, Congress must give the Food and Drug Administration the tools it needs to review and approve these products," Senate Majority Leader Harry Reid stated on the Senate floor.

"Israel Neurology Devices Market Outlook to 2018 - Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices and Others" provides key market data on the Israel Neurology Devices market.

Med-tech isn't much different than any other sector of the market; when the growth goes, so do the investors.

As part of our process, we perform a rigorous discounted cash-flow methodology that dives into the true intrinsic worth of companies.

Renal denervation. This is something I had never heard about until St. Jude Medical mentioned it at their February analyst day after first disclosing it in late 2011 .

Editor's Note: The following guest post is published with the permission of its author, Edward J. Schloss, MD, the medical director of cardiac electrophysiology at Christ Hospital in Cincinnati , OH.

St Jude Medical Inc said it won European approval to begin selling a device that lowers blood pressure by creating tiny scars along the renal nerves, joining a growing number of medical technology companies developing hypertension treatments.

St. Jude Medical, Inc. , a global medical device company, today announced that data from the FAME II trial demonstrated a significant difference in the need for urgent revascularization when Fractional Flow Reserve -guided assessment was used to direct treatment in patients with stable coronary artery disease.

St. Jude Medical, Inc. , a global medical device company, today announced CE Mark Approval and launch of its EnligHTNa renal denervation system during EuroPCR.

NEW YORK &#8212 St. Jude Medical Inc. stock rose Monday after a Goldman Sachs analyst upgraded the medical device maker's shares, saying they should bounce back as sales of new devices improves and as St.

While the rest of the stock market was awash in a sea of red, shares of medical device maker St.

St. Jude Medical Inc.'s Riata defibrillator lead -- a wire that connects the lifesaving device to the heart -- fails at a much higher rate than previously thought and three times what is considered acceptable, according to a study by a Minneapolis Heart Institute cardiologist.

Michael W. Minton has a device in his chest that could save his life by helping his heart beat properly.

St. Jude Medical, Inc. , a global medical device company, today announced results of the SCD-HeFT 10-Year Follow-up Study at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions in Boston.

St. Jude Medical Inc. said Tuesday the U.S. Food and Drug Administration has approved a new defibrillator the company says helps prevent unnecessary shocks to the heart.

St. Jude Medical, Inc. , a global medical device company, today announced U.S. Food and Drug Administration approval of its Ellipsea implantable cardioverter defibrillator .

Shares of Pluristem Therapeutics pop on the news that the use of the its PLacental eXpanded cells saved the life of a child, following a bone marrow transplant failure.

St. Jude Medical popped more than 3% Wednesday after a Morgan Stanley analyst upgraded the stock to Overweight, predicting that fundamentals will start to outweigh recent concerns about its implantable heart devices.

James Barrow , the manager of Vanguard Windsor II and Selected Value Funds reported his second quarter portfolio.